Clinical Trial

A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)

Study acronym: KANNON
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
It is a phase Ⅱ,open-label, single-line, Multiple cohorts, Multicenter study assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins mutation patients with Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-25; most recent amendment 2026-05-20.
Status change: Recruiting → Active, Not Recruiting 2026-05-20
Trial Details
NCT Number NCT06015503
Lead Sponsor Avistone Biotechnology Co., Ltd.
Conditions NSCLC (Non-small Cell Lung Cancer)
Enrollment 139 participants
Start Date 2023-07-21
Primary Completion 2025-03-06 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-22